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INTRODUCTION
Immune thrombocytopenic purpura (ITP) is an autoim-
mune disorder characterized by accelerated platelet destruc-
tion (1). The spleen is the primary site of platelet destruc-
tion and antiplatelet antibody production, and the mainstay
medical therapy is bolus corticosteroids followed by a taper-
ing dose. However, long-term remission rates are only 20%
to 25% in adults, and for patients who continue to require
steroids or who fail to respond to high-dose corticosteroids,
splenectomy is considered a second-line therapy (2). 
Laparoscopic splenectomy (LS) was first reported in 1992
(3), and is now used to treat a number of hematologic diseases,
including ITP. Several reports that have compared the results
of open splenectomy and LS for ITP have concluded that LS
results in fewer postoperative complications (4, 5). However,
no difference was found in remission rates. LS has the follow-
ing advantages; reduced operative trauma, less splenosis, bet-
ter detection of accessory spleens, less post-operative pain,
cosmetic advantages, early discharge (mostly within 48 hr
after surgery), and it allows patients to resume normal activi-
ty within a few days (6-9). However, prognostic indicators
are important because for patients with an expected good
response to LS the benefits of the procedure would justify the
associated risks. However, previous attempts to identify factors
that predict LS success have led to conflicting results (10-13).
Here we report on the intermediate follow-up results of
30 patients who underwent LS because of nonresponsive or
refractory ITP. We also retrospectively analyzed preoperative




From May 1997 to December 2002, 30 ITP patients who
had not responded to medical treatment underwent LS at
the Department of Surgery at Dong-A University Medical
Center, Busan, Korea. ITP was diagnosed according to the
guidelines of the American Society of Hematology (2). All
patients underwent bone marrow aspiration and other caus-
es of thrombocytopenia were ruled out.
All 30 patients had been treated with prednisone at an
initial dose of 1 mg/kg/day for one month, which was then
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Prognostic Factors of Response to Laparoscopic Splenectomy in
Patients with Idiopathic Thrombocytopenic Purpura
Laparoscopic splenectomy (LS) has become the treatment of choice for patients
with idiopathic thrombocytopenic purpura (ITP) who do not respond to medical
treatment. The aim of this study was to identify factors predictive of outcome after
LS for ITP. From May 1997 to December 2002, we performed 30 LS on patients
with ITP. A positive response was defined as a postoperative platelet count greater
than 50,000/ L and no requirement for maintenance therapy. Chi-square testing
was performed to determine the predictive effects of the following variables: age,
sex, preoperative response to steroids or immunoglobulin, duration of disease,
antiplatelet antibody, platelet associated antibody, and antinuclear antibody. LS
was successfully performed in all patients. For a mean follow-up interval of 24.3
months, response to LS was 73.3%. Splenectomy for steroid nonresponders
resulted in an inferior complete response rate (10 of 18, 55.6%) as compared with
those that experienced relapse after steroid treatment (11 of 12, 91.7%) (p=0.042).
The other significant predictor of outcome by univariate analysis was the time
between diagnosis and surgery (p=0.049). The other variables showed no signifi-
cant correlation with successful splenectomy. We conclude that LS can be per-
formed safely with a satisfactory remission rate in patients with ITP who do not
respond to medical treatment, and that the factors most frequently associated with
surgical success are a response to steroid and disease duration. 
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tapered to the minimal effective dose required to maintain
platelets at >30,000/ L. Those who were refractory to steroid
therapy, relapsed during steroid tapering, intolerant to medi-
cal treatment, pregnant, and those actively bleeding with
platelet counts <30,000/ L were selected for splenectomy.
The patients were administered a polyvalent pneumococcal
vaccine at least 2 weeks before surgery, and 400 mg of intra-
venous immunoglobulin G (IVIG) per kilogram of body
weight for five consecutive days immediately prior to laparo-
scopic splenectomy. 
Operation technique
The detailed operative procedure has been described (14).
Briefly, patients were placed in a right lateral position, and
the procedure was performed through 5-10 mm incisions.
Abdomens were insufflated with CO2, and three laparoscop-
ic ports were introduced to allow a laparoscope and surgical
instruments access to the abdominal cavity. In each case, the
spleen was mobilized by dividing peritoneal attachments and
ligaments by electrocautery. The left upper quadrant, spleno-
colic ligament, splenic hilum, lesser sac, root of the small
bowel mesentery, and pelvis were routinely explored, and
accessory spleens were removed. Spleens were placed in a plas-
tic bag, the opening of which was delivered out through the
most lateral port. Specimen were mechanically fracture-morse-
lized via the exteriorized extraction bag. After withdrawing
the spleen, the operative field was irrigated with normal saline,
and the possibility of bleeding or of a missed accessory spleen
investigated. 
Clinical outcome and follow-up
In this study we adopted the definition of hematologic out-
come suggested by Radaelli et al. (15). Complete response
(CR) was defined as a rise in the platelet count to >100,000/ L
for at least 6 months (with or without treatment), partial res-
ponse (PR) was defined as a platelet count of 50,000-100,000/
L, and refractory disease (no response, NR) was defined no
platelet count increase postoperatively or a platelet count of
<50,000/ L during treatment. For the statistical analysis
patients were subdivided into two groups, namely, respon-
der (CR+PR) and non-responder (NR) groups. We checked
the platelet count at 1, 2, 4, and 8 weeks, and thereafter we
followed the patients at 3-month intervals for 1 yr, and then
annually. Immediate response to splenectomy was determined
within 6 months of surgery and the long-term response from
6 months to 7 yr after surgery.
Prognostic factors of laparoscopic splenectomy outcome
Patient age, sex, prior response to steroids, response to IVIG,
time from diagnosis to splenectomy, and positivity to anti-
platelet antibody, platelet associated antibody, and antinu-
clear antibody (ANA) were evaluated to identify the charac-
teristics of responders to LS. Categorical and numerical data
were evaluated using the chi-square and Mann-Whitney tests,
and pvalue of <0.05 was considered statistically significant. 
RESULTS
Patient’s characteristics and the outcome of splenectomy
The mean age of the 30 patients enrolled in this study was
28 yr (range, 3-71). There were 7 males (23%) and 23 females
(67%), and 7 were pediatric patients. The mean time from
diagnosis to splenectomy was 7.5 months (range, 1-88.8).
Surgical indications included disease refractory to medical
treatment (18/30, 60%), or recurrence during tapering (12/30,
40%).
All 30 patients successfully underwent LS without the need
for conversion to open splenectomy. There were no periop-
erative deaths. Three patients (10%) experienced transient
postoperative complications, namely, infections, subphrenic
abscesses, and minor wound hematomas, respectively. The
mean operative time for LS was 117.5 min (range, 80-360),
and the mean postoperative hospital stay was 4 days (range,
2-15). Accessory spleens were found and removed in five
patients (16.7%), and two of these patients had two accesso-
ry spleens. The locations of the accessory spleen were; near
the hilum, and on the greater omentum and splenocolic lig-
ament.
At a mean follow-up of 24.3 months, the initial response
rate was 73.3% (CR in 15/30 [50%], and PR in 7/30 [23.3%]).
All eight non-responders underwent radionucleotide spleen
scans, and one of these eight was found to have an accessory
spleen, which was successfully removed laparoscopically. In
this patient, the thrombocytopenia recurred 12 months after
surgery. The platelet count rose following the removal of the
accessory spleens, and this patient has been in remission for
14 months. Four patients had never been administered post-
operative medication for ITP because they were asymptomat-
ic and had platelet counts between 30,000 and 50,000/ L.
Three patients were treated with high dose dexamathasone
(40 mg intravenously for 4 days), however no definite response
was observed, and these patients continue to take danazol
and/or vincristine intermittently to maintain platelet count
levels. One patient with an initial response to LS subsequent-
ly developed recurrent disease which required no treatment.
Therefore, the overall remission rate was 73.3% (22 of 30).
Prognostic factors of response
The relationship between the investigated variables and
LS remission rates for ITP are listed in Table 1. Preoperative
responsiveness to steroid therapy was found to be significant-
ly correlated with response to LS. Moreover, splenectomy forLaparoscopic Splenctomy for ITP 419
steroid nonresponders resulted in an poorer CR rate (10 of
18, 55.6%) than for those who relapsed after steroid treat-
ment (11 of 12, 91.7%) (p=0.042). The other significant pre-
dictor of a satisfactory outcome by univariable analysis was
the time between diagnosis and surgery. Patients with a dis-
ease duration >12 months had a higher response than those
with a duration less than this (92.3% vs. 52.9%, respective-
ly) (p=0.049), and pediatric patients responded better (6/7,
85.7%) than adults (16/23, 69.6%), but without significance
(p=0.393). When we analyzed the data after excluding pedi-
atric patients, no difference in response rate was found between
those older and younger than 40 yr old (71.4% vs. 62.5%,
respectively, p=1.000). The mean operative time for respon-
ders was 129±59 min, and for non-responder 149±53 min
(p=0.385). Not all patients received serologic tests for anti-
platelet antibody, platelet associated antibody, and ANA, but
the test results obtained showed no relation with LS response.
And, the other variables examined were not found to be pre-
dictive of successful splenectomy. 
DISCUSSION
The recent emergence of minimally invasive techniques
has increased interest in splenectomy for a variety of hema-
tologic illnesses, including ITP. The response rate of LS for
ITP is reported to be 64% to 90% (6-13); however, it is dif-
ficult to compare study results. Most LS reports are retrospec-
tive in nature, involve data collections over protracted peri-
ods of time, and have failed to follow patients systematically
and prospectively. Furthermore, there does not appear to be
any standard definition of disease remission and follow-up
duration, and whereas some authors define disease remission
as the normalization of platelet count, other have defined it
to be a normalization of platelet count without the need for
future medical therapy. In the present study, we defined dis-
ease remission as a sustained platelet count of >50,000/ L
without the need for medical therapy. We obtained an over-
all remission rate of 73.3% at a median follow-up of 24.3
months, which concurs with other reports (6-13). 
The natural history of ITP differs in adults and children.
Spontaneous remission, independent of treatment, occurs in
>80% of children with the disease, and when necessary, splen-
ectomy is nearly always curative in children (16, 17). The
guidelines issued by the American Society of Hematology
recommend that splenectomy be considered for children who
have had ITP for at least one year with symptomatic severe
thrombocytopenia (2). In the present study, the enrolled pedi-
atric patients had an ITP duration of >12 months and were
refractory to steroid or IVIG, and most responded well after
LS (6/7, 85.7%). 
The overlooking of accessory spleens is a major cause of LS
failure in ITP. In the present study the accessory spleen rate
was 16.7%, which is comparable to the rates (5-21%) report-
ed for ITP patients that have undergone LS (9, 12). One of
our patients with postsurgical ITP recurrence was found to
have an accessory spleen, which was removed successfully by
using a laparoscopic procedure.
Many investigators have sought to identify the preopera-
tive variables that predict a successful outcome following LS;
however, the results obtained were often divergent (9-13). In
the present study we considered some of the parameters pre-
viously examined in the literature, such as, age, sex, response
to initial steroid treatment and/or IVIG therapy, time between
diagnosis and surgery, and positivity for anti-platelet anti-
body, platelet associated antibody, and ANA. However, we
did not evaluate platelet kinetics or platelet sequestration
because the guidelines published by the American Society
of Hematology deems them unnecessary (2).
Our results show that an initial response to steroid treat-
ment is significantly associated with a positive response to
LS. This correlation has been previously reported (9), although
a more recent study failed to identify a significant association
(12). In the present study, the other significant prognostic
factor of successful LS identified was the time from diagno-
sis to LS. Specifically, patients who received LS >12 months
after diagnosis had a better response. This finding may be due
to most patients with previous responded to steroid therapy
(10 out of 12 patients) and all of the pediatric patients had
time between diagnosis and LS was more than 12 months.
It is not similar with other results (18).
IVIG, intravenous immunoglobulin G; ANA, antinuclear antibody.
Variables Responder Non-responder p
Age 
<15 yr (n=7) 6 (85.7%) 1 (14.3%) 0.393
≥15 yr (n=23) 15 (65.2%) 8 (34.8%)
Sex
Male (n=7) 4 (57.1%) 3 (42.9%) 1.000
Female (n=23) 17 (73.9%) 6 (26.1%)
Disease duration
<12 months (n=17) 9 (52.9%) 8 (47.1%) 0.042
≥12 months (n=13) 12 (92.3%) 1 (7.7%)
Response to steroid
+ (n=12) 11 (91.7%) 1 (8.3%) 0.049
- (n=18) 10 (55.6%) 8 (44.4%)
Response to IVIG*
+ (n=18) 13 (72.2%) 5 (27.8%) 1.000
- (n=12) 8 (66.7%) 4 (33.3%)
Anti-platelet antibody
+ (n=7) 5 (71.4%) 2 (28.6%) 1.000
- (n=18) 11 (61.1%) 7 (38.9%)
Platelet associated antibody
+ (n=13) 7 (53.8%) 6 (46.2%) 0.411
- (n=12) 9 (75.0%) 3 (25.0%)
ANA
�
+ (n=7) 4 (57.1%) 3 (42.9%) 1.000
- (n=13) 8 (61.5%) 5 (38.5%)
Table 1. Patients’ characteristics related to the response to laparo-
scopic splenectomy420 H.-C. Kwon, C.H. Moon, Y.R. Cho, et al.
Patient age has most often been identified as a predictor
of a successful response to LS (9-12, 19). Several studies have
shown that an age between 30 and 45 years is an significant
prognostic indicator of successful LS (10, 11, 19). However,
other studies have produced different results (9, 12). The pre-
dictive strength of preoperative response to IVIG is also con-
troversial. One study demonstrated a significant correlation
between response to IVIG and sustained response to splenec-
tomy (18), whereas other studies disagree (11, 15). These dis-
crepancies between studies are probably due to the different
ages of the populations studied and the varying lengths of
follow-up. 
Recently, the long-term outcomes of a group of adult chron-
ic ITP patients after splenectomy failure were reported. It
was found that most patients with refractory ITP eventually
achieved stable remission, but it was emphasized that this
occurred slowly (20). In the present study, 50% of the patients
had a platelet count of 30,000-50,000/ L after LS, and these
patients did not require medication. And, although it has
been reported that refractory ITP patients may respond to
high dose dexamethosone therapy (21), in the present study
we did not observe same result. In conclusion, our results
indicated that an initial response to steroid and a period of
more than 12 months between diagnosis and LS are positive
predictors of long-term remission in ITP.
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